Author + information
- Received April 6, 2018
- Revision received June 20, 2018
- Accepted June 20, 2018
- Published online July 30, 2018.
- Kishan S. Parikh, MDa,b,∗ (, )
- Kavita Sharma, MDc,
- Mona Fiuzat, PharmDa,b,
- Howard K. Surks, MDd,
- Jyothis T. George, MDe,
- Narimon Honarpour, MD, PhDf,
- Christopher Depre, MD, PhDf,
- Patrice Desvigne-Nickens, MDg,
- Richard Nkulikiyinka, MDh,
- Gregory D. Lewis, MDi,
- Mardi Gomberg-Maitland, MD, MScj,
- Christopher M. O’Connor, MDj,
- Norman Stockbridge, MDk,
- Robert M. Califf, MDb,l,m,
- Marvin A. Konstam, MDn,
- James L. Januzzi Jr., MDo,
- Scott D. Solomon, MDp,
- Barry A. Borlaug, MDq,
- Sanjiv J. Shah, MDr,
- Margaret M. Redfield, MDq and
- G. Michael Felker, MDa,b
- aDuke Clinical Research Institute, Durham, North Carolina
- bDuke University School of Medicine, Durham, North Carolina
- cJohns Hopkins University, Baltimore, Maryland
- dSanofi, Bridgewater, New Jersey
- eBoehringer Ingelheim Clinical Development, Ingelheim, Germany
- fAmgen, Inc., Thousand Oaks, California
- gNational Institutes of Health, National Heart, Lung, and Blood Institute, Bethesda, Maryland
- hBayer AG, Wuppertal, Germany
- iMassachusetts General Hospital, Boston, Massachusetts
- jInova Heart and Vascular Institute, Falls Church, Virginia
- kU.S. Food and Drug Administration, Silver Spring, Maryland
- lStanford University, Stanford, California
- mVerily Life Sciences, San Francisco, California
- nTufts Medical Center, Boston, Massachusetts
- oBrigham and Women’s Hospital, Boston, Massachusetts
- pHarvard Medical School, Wellesley, Massachusetts
- qMayo Clinic, Rochester, Minnesota
- rNorthwestern University, Chicago, Illinois
- ↵∗Address for correspondence:
Dr. Kishan S. Parikh, Duke Clinical Research Institute, PO Box 17969, Durham, North Carolina 27715.
The number of persons with heart failure has continued to rise over the last several years. Approximately one-half of those living with heart failure have heart failure with preserved ejection fraction, but critical unsolved questions remain across the spectrum of basic, translational, clinical, and population research in heart failure with preserved ejection fraction. In this study, the authors summarize existing knowledge, persistent controversies, and gaps in evidence with regard to the understanding of heart failure with preserved ejection fraction. Our analysis is based on an expert panel discussion “Think Tank” meeting that included representatives from academia, the National Institutes of Health, the U.S. Food and Drug Administration, the Centers for Medicare & Medicaid Services, and industry.
- classification scheme
- ejection fraction
- heart failure
- preserved ejection fraction
- pulmonary hypertension
- subject eligibility
Dr. Fiuzat has received personal fees from ResMed outside the submitted work. Dr. Surks is an employee of Sanofi. Dr. George is an employee of Boehringer Ingelheim. Dr. Honarpour is an employee of Amgen and has received stock grants from Amgen, Inc. Dr. Depre is an employee of Amgen, Inc. Dr. Nkulikiyinka is an employee and shareholder of Bayer AG. Dr. Lewis has received grants from Abbott Vascular, Ironwood, National Institutes of Health, and American Heart Association; and is a consultant for Amgen, Luitpold, and Cytokinetics. Dr. Gomberg-Maitland has received grants and other support from Actelion; personal fees from Bayer, Acceleron, Medronic, Arena, Merck, St. Jude’s/Abbott, and Liquidia; other support from Reata and PCORI; grants, personal fees, and other support from United Therapeutics; grants from AADi; and personal fees from Janssen during the conduct of the study. Dr. O’Connor has received personal fees from ResMed, Bayer, Stealth Peptides, Bristol-Myers Squibb Foundation, Dey, L.P., and Merck outside the submitted work. Dr. Califf served as Commissioner for Food and Drugs at the U.S. Food and Drug Administration from 2016 to 2017 and as Deputy Commissioner for Medical Products and Tobacco from 2015 to 2016; is employed as a scientific advisor by Verily Life Sciences (Alphabet); has received stock from Verily Life Sciences; is a consultant for Merck, Amgen, and Boehringer Ingelheim; and receives consulting payments from Merck. Dr. Konstam has received other support from Amgen, Bristol-Myers Squibb, Boehringer Ingelheim, and Novartis; and grants and other support from Ironwood and Livanova outside the submitted work. Dr. Januzzi has received grants from Roche Diagnostics, Abbott, Singulex, Prevencio, and Novartis; grants and personal fees from Janssen; and personal fees from Critical Diagnostics outside the submitted work. Dr. Solomon has received grants and personal fees from Novartis, AstraZeneca, Bayer, Bristol-Myers Squibb, Alnylam, GlaxoSmithKline, Myokardia, and Amgen; grants from Ionis; and personal fees from Corvia, Roche, and Merck outside the submitted work. Dr. Shah has received receiving research funding from the National Institutes of Health (R01 HL107577, R01 HL127028), the American Heart Association (#16SFRN28780016 and #15CVGPSD27260148), Actelion, AstraZeneca, Corvia, and Novartis; and consulting fees from Actelion, Amgen, AstraZeneca, Bayer, Boehringer Ingelheim, Cardiora, Eisai, Ironwood, Merck, Novartis, Sanofi, Tenax, and United Therapeutics. Dr. Felker has received grant funding from National Heart, Lung, and Blood Institute, American Heart Association, Novartis, Amgen, Cytokinetics, Merck, and Roche Diagnostics; and consulting for Novartis, Amgen, Roche Diagnostics, Medtronic, Bristol-Myers Squibb, GlaxoSmithKline, Cardionomic, Cytokinetics, Myokardia, Stealth, Innolife, and EBR Systems. All other authors have reported that they have no relationships relevant to the contents of this paper to disclose. Barry H. Greenberg, MD, served as Guest Editor for this paper.
- Received April 6, 2018.
- Revision received June 20, 2018.
- Accepted June 20, 2018.
- 2018 American College of Cardiology Foundation
- Central Illustration
- Is HFpEF a Single Entity?
- Is a Clinically Based Scheme the Right Approach to HFpEF Classification?
- Should Clinical Trials Continue to Address All HFpEF Similarly?
- Should HFpEF Trials Use Quality-of-Life Metrics as Main Endpoints?